Inhaled Nitric Oxide for Patients With MABSC
A Prospective, Open Labeled, Multi-Center, Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With NTM (Specifically MABSC)
Sponsor: Beyond Air Inc.
This PHASE2 trial investigates Mycobacterium Abscessus Infection and is currently completed. Beyond Air Inc. leads this study, which shows 10 recorded versions since 2017 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Sep 2019 — Nov 2020 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Aug 2019 — Sep 2019 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Jun 2018 — Aug 2019 [monthly]
Recruiting PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Jan 2018 [monthly]
Recruiting PHASE2
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beyond Air Inc.
For direct contact, visit the study record on ClinicalTrials.gov .